Cargando…

Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study

Objective. To investigate if antibodies towards biological TNF-α inhibitors (anti-TNFi Abs) are present in patients with rheumatoid arthritis (RA) in clinical remission and to relate any anti-TNFi Abs to circulating level of TNF-α inhibitor (TNFi). Methods. Patients with RA, treated with infliximab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eng, Grith P., Bendtzen, Klaus, Bliddal, Henning, Stoltenberg, Michael, Szkudlarek, Marcin, Fana, Viktoria, Lindegaard, Hanne M., Omerovic, Emina, Højgaard, Pil, Jensen, Elmo K., Bouchelouche, Pierre N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339793/ https://www.ncbi.nlm.nih.gov/pubmed/25759761 http://dx.doi.org/10.1155/2015/784825

Ejemplares similares

Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study
por: Eng, Grith Petersen, et al.
Publicado: (2016)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Feasibility of a standardized ultrasound examination in patients with rheumatoid arthritis: a quality improvement among rheumatologists cohort
por: Ellegaard, Karen, et al.
Publicado: (2012)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial
por: Buhl, Sine Schnoor, et al.
Publicado: (2014)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Adalimumab/infliximab: Lower serologic response: 6 case reports
Publicado: (2022)

Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis
por: Mase, Oliver, et al.
Publicado: (2023)

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study
por: Ortea, Ignacio, et al.
Publicado: (2016)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
por: Kimura, Noriko, et al.
Publicado: (2019)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
por: Doan, Quan V., et al.
Publicado: (2006)

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
por: van der Bijl, Arie E., et al.
Publicado: (2008)

Biologic-free remission by orthopaedic surgery in non-responder to infliximab for rheumatoid arthritis
por: Kanbe, Katsuaki, et al.
Publicado: (2015)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
por: Goncalves, Joao, et al.
Publicado: (2019)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Use of Adalimumab in young patients with chronic uveitis in whom infliximab loses its efficacy
por: Giani, TG, et al.
Publicado: (2008)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab
por: Gorovits, B., et al.
Publicado: (2018)

Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay
por: Papamichael, Konstantinos, et al.
Publicado: (2020)

Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
por: Campanilho-Marques, Raquel, et al.
Publicado: (2020)

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
por: Prens, L.M., et al.
Publicado: (2021)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Adalimumab/golimumab/infliximab: SARS-CoV-2 pneumonia: 3 case reports
Publicado: (2021)

The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
por: Barszczewska, Olga, et al.
Publicado: (2021)

Corrigendum to: Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
Publicado: (2021)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

Remission of Refractory Celiac Disease With Infliximab in a Pediatric Patient
por: Rawal, Nidhi, et al.
Publicado: (2015)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mravvmb9es69lltenv8gig4ad8